5:09 PM
 | 
Apr 01, 2013
 |  BC Extra  |  Company News

Daiichi returning AKT compounds to ArQule

ArQule Inc. (NASDAQ:ARQL) said partner Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) is terminating a deal that gave the pharma exclusive, worldwide rights to a portfolio of protein kinase B (PKB; PKBA; AKT; AKT1) compounds for cancer. The portfolio's lead compound, ARQ...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >